Edwards Lifesciences Corp (NYSE: EW) has seen a decline in its stock price by -0.19 in relation to its previous close of 85.25. However, the company has experienced a -1.00% decline in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-05-01 that Here is how Edwards Lifesciences (EW) and SNDL Inc. (SNDL) have performed compared to their sector so far this year.
Is It Worth Investing in Edwards Lifesciences Corp (NYSE: EW) Right Now?
The price-to-earnings ratio for Edwards Lifesciences Corp (NYSE: EW) is above average at 36.57x, Company’s 36-month beta value is 1.12.Analysts have differing opinions on the stock, with 9 analysts rating it as a “buy,” 7 as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for EW is 593.08M, and currently, short sellers hold a 1.24% ratio of that floaft. The average trading volume of EW on May 07, 2024 was 3.74M shares.
EW’s Market Performance
The stock of Edwards Lifesciences Corp (EW) has seen a -1.00% decrease in the past week, with a -8.21% drop in the past month, and a -1.13% fall in the past quarter. The volatility ratio for the week is 2.10%, and the volatility levels for the past 30 days are at 2.21% for EW. The simple moving average for the past 20 days is -3.33% for EW’s stock, with a 8.44% simple moving average for the past 200 days.
Analysts’ Opinion of EW
Wells Fargo, on the other hand, stated in their research note that they expect to see EW reach a price target of $94. The rating they have provided for EW stocks is “Overweight” according to the report published on February 02nd, 2024.
Evercore ISI gave a rating of “In-line” to EW, setting the target price at $77 in the report published on January 04th of the current year.
EW Trading at -5.37% from the 50-Day Moving Average
After a stumble in the market that brought EW to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.48% of loss for the given period.
Volatility was left at 2.21%, however, over the last 30 days, the volatility rate increased by 2.10%, as shares sank -7.85% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.02% lower at present.
During the last 5 trading sessions, EW fell by -1.00%, which changed the moving average for the period of 200-days by -8.16% in comparison to the 20-day moving average, which settled at $87.66. In addition, Edwards Lifesciences Corp saw 11.59% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EW starting from MUSSALLEM MICHAEL A, who sale 29,350 shares at the price of $84.77 back on May 02 ’24. After this action, MUSSALLEM MICHAEL A now owns 4,486 shares of Edwards Lifesciences Corp, valued at $2,487,966 using the latest closing price.
Lemercier Jean-Luc M, the CVP, EMEACLA and JAPAC of Edwards Lifesciences Corp, sale 14,400 shares at $84.21 during a trade that took place back on May 01 ’24, which means that Lemercier Jean-Luc M is holding 173,849 shares at $1,212,687 based on the most recent closing price.
Stock Fundamentals for EW
Current profitability levels for the company are sitting at:
- 0.26 for the present operating margin
- 0.77 for the gross margin
The net margin for Edwards Lifesciences Corp stands at 0.23. The total capital return value is set at 0.18. Equity return is now at value 21.59, with 15.38 for asset returns.
Based on Edwards Lifesciences Corp (EW), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at 0.85. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is 56.96.
Currently, EBITDA for the company is 1.95 billion with net debt to EBITDA at -0.28. When we switch over and look at the enterprise to sales, we see a ratio of 8.26. The receivables turnover for the company is 7.01for trailing twelve months and the total asset turnover is 0.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.75.
Conclusion
In a nutshell, Edwards Lifesciences Corp (EW) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
